title: At what stage does pancreas allograft rejection become irreversible?: an experimental study.
abstract: BACKGROUND
  It is commonly believed that abnormal blood glucose levels indicate irreversible rejection. We were interested in determining the stage at which rejection remains reversible.
  
  
  METHODS
  A total of 54 Lewis rats were rendered diabetic with 55 mg/kg streptozocin and were then given a pancreas transplant from Brown Norway donors. Pancreatic juice was collected in a subcutaneous reservoir. All recipients received 15 mg/kg cyclosporine A (CsA) for 5 days. CsA was then discontinued for 2 days (n=7, group 1), 4 days (n=7, group 2), 6 days (n=9, group 3), 8 days (n=9, group 4), 9 days (n=11, group 5), and 10 days (n=11, group 6). Two animals of each group were euthanized at the end of the immunosuppressive-free interval, for histological assessment of the grade of rejection (G0, GI, GII, GIII). Rejection was treated with methylprednisolone (7 mg/kg body weight) and CsA (15 mg/kg body weight). The volume of pancreatic juice, together with juice cytology (C0, CI, CII) and blood glucose levels, was assessed daily.
  
  
  RESULTS
  Blood glucose remained normal throughout the observation period in animals with GI and GII rejection. The numbers of animals that became diabetic were as follows: 5 of 9 (group 4), 7 of 11 (group 5), and 8 of 11 (group 6). Decreased amounts of pancreatic juice were observed in all animals, except those in group 1. The histology returned to normal after anti-rejection therapy in four animals (57%) of group 1, in two animals (28%) of group 2, and in one animal (11%) of groups 3 and 4, respectively. Although there was no animal in groups 5 and 6 with normal graft histology after treatment, there were still four (36%) and three (27%) animals, respectively, that were normoglycemic and that had pancreatic grafts with well-preserved islets.
  
  
  CONCLUSIONS
  From these data, we conclude that even GIII rejection with severe endothelialitis and isleitis can be reversed. Therefore, we suggest that a trial of enhanced immunosuppression is justified in patients with advanced pancreas allograft rejection.
authors.affiliation: Department of Transplant Surgery, University of Innsbruck, Austria.
authors.forename: A
authors.initials: A
authors.lastname: Königsrainer
authors.forename: W
authors.initials: W
authors.lastname: Mark
authors.forename: P
authors.initials: P
authors.lastname: Hechenleitner
authors.forename: G
authors.initials: G
authors.lastname: Klima
authors.forename: O
authors.initials: O
authors.lastname: Dietze
authors.forename: R
authors.initials: R
authors.lastname: Margreiter
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D006084:Graft Rejection / Q000473:pathology*; D016035:Pancreas Transplantation / Q000473:pathology*; D010189:Pancreatic Juice / Q000378:metabolism; D051381:Rats; D011917:Rats, Inbred Lew; D014184:Transplantation, Homologous
chemical_list: D001786:Blood Glucose